Reactions 1704, p49 - 2 Jun 2018 Acute weight loss: case report In a multi-centre retrospective study of 148 patients, one patient [age and sex not stated] was described, who developed acute weight loss during treatment with apremilast for plaque psoriasis [dosage, route and duration of treatment to reaction onset not stated]. The patient, who had plaque psoriasis, started receiving combination treatment with apremilast along with an unspecified therapy. Eventually, the patient developed significant acute weight loss, which required admission to the emergency department. Subsequently, the weight loss stabilised and the treatment with apremilast was continued. Author comment: "One patient receiving [combination therapy] experienced a severe [adverse event] was admitted to the emergency department on account of significant acute weight loss." "Efficacy . . . and safety (reported adverse events [AEs]) were assessed from baseline to week 16 (discontinuations were considered nonresponse)." Ighani A, et al. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. Journal of the American Academy of Dermatology 78: 623-626, No. 3, Mar 2018. Available from: URL: http://doi.org/10.1016/j.jaad.2017.09.060 - Canada 803323372 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera